ReviewAdvances in parasitology2017
Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.
Review in Advances in parasitology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 114 citations in OpenAlex.
- Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.Nature communications · 2024Trial
- ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.PLoS neglected tropical diseases · 2023Trial
- Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).Antimicrobial agents and chemotherapy · 2023Trial
- Conjugates of α-d-Galp-(1→3)-β-d-Galp for the serological diagnosis of Chagas disease.PLoS neglected tropical diseases · 2026Article
- Conjugation of Saccharidic Synthetic Antigens with Carrier Proteins by the Squaric Acid Method: Application as Biomarkers for Treatment Evaluation in Chagas Disease.Methods in molecular biology (Clifton, N.J.) · 2026Article
- The Role of Immunogenetics in the Host-Parasite Interaction of Chagas Disease: Implications for Personalized Medicine.Tropical medicine and infectious disease · 2025Review
- K-mer-based approach for serodiagnostic antigen discovery in Chagas disease using unassembled sequencing reads.PLoS neglected tropical diseases · 2025Article
- Evaluation of a Novel Tc-24 Recombinant Antigen ELISA for Serologic Detection of Trypanosoma cruzi Infection in Dogs: A Pilot Study.Veterinary medicine and science · 2025Article
- Prevalence and diagnostic accuracy of different diagnostic tests for Chagas disease in an indigenous community of the Paraguayan Chaco.PLoS neglected tropical diseases · 2025Article
- A Review on the Epidemiology and Clinical Management of Neglected Tropical Diseases.Infectious disorders drug targets · 2025Review
- The carbonic anhydrase enzymes as new targets for the management of neglected tropical diseases.Archiv der Pharmazie · 2025Review
- The use of rapid diagnostic tests for chronic Chagas disease: An expert meeting report.PLoS neglected tropical diseases · 2024Review
- Chagas disease in the United States: a call for increased investment and collaborative research.Lancet regional health. Americas · 2024Review
- The use of peptides for immunodiagnosis of human Chagas disease.Amino acids · 2024Review
- Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas disease: a scoping review.Frontiers in microbiology · 2024Article
- New insights intoFrontiers in immunology · 2024Review
- An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.PLoS neglected tropical diseases · 2024Article
- Galectins in Protozoan Parasitic Diseases: Potential Applications in Diagnostics and Therapeutics.Cells · 2023Review
- What Do You Need to Know before Studying Chagas Disease? A Beginner's Guide.Tropical medicine and infectious disease · 2023Review
- Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model.Pharmaceuticals (Basel, Switzerland) · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a lifelong and debilitating illness of major significance throughout Latin America and an emergent threat to global public health. Being a neglected disease, the vast majority of Chagasic patients have limited access to proper diagnosis and treatment, and there is only a marginal investment into R&D for drug and vaccine development. In this context, identification of novel biomarkers able to transcend the current limits of diagnostic methods surfaces as a main priority in Chagas disease applied research. The expectation is that these novel biomarkers will provide reliable, reproducible and accurate results irrespective of the genetic background, infecting parasite strain, stage of disease, and clinical-associated features of Chagasic populations. In addition, they should be able to address other still unmet diagnostic needs, including early detection of congenital T. cruzi transmission, rapid assessment of treatment efficiency or failure, indication/prediction of disease progression and direct parasite typification in clinical samples. The lack of access of poor and neglected populations to essential diagnostics also stresses the necessity of developing new methods operational in point-of-care settings. In summary, emergent diagnostic tests integrating these novel and tailored tools should provide a significant impact on the effectiveness of current intervention schemes and on the clinical management of Chagasic patients. In this chapter, we discuss the present knowledge and possible future steps in Chagas disease diagnostic applications, as well as the opportunity provided by recent advances in high-throughput methods for biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.